With 23.6 million shares changed hands, the volume of the stock remained lighter than its average volume of 26.89 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.17 whereas the lowest price it dropped to was $0.1395. The 52-week range on APLM shows that it touched its highest point at $1.23 and its lowest point at $0.08 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 1.40.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APLM was up-trending over the past week, with a rise of 37.26%, but this was up by 20.10% over a month. Three-month performance surged to 25.42% while six-month performance fell -47.17%. The stock lost -78.38% in the past year, while it has lost -82.97% so far this year.
Float and Shares Shorts:
At present, 89.50 million APLM shares are outstanding with a float of 66.39 million shares on hand for trading. On 2024-10-31, short shares totaled 0.17 million, which was 15.0 higher than short shares on 1727654400. In addition to Dr. Guo-Liang Yu Ph.D. as the firm’s Co-Founder, CEO & Executive Chairman, Dr. Matthew James Plunkett Ph.D. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.02089 of APLM’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APLM since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$0.66 being high and -$0.66 being low. For APLM, this leads to a yearly average estimate of -$0.66.
